Lipid-polymer hybrid nanoparticles: a cutting-edge frontier in breast cancer treatment strategies.

Breast cancer remains one of the most prevalent and deadly cancers worldwide, affecting women. This review explores the potential of lipid-polymer hybrid nanoparticles (LPHNPs) as a next-generation drug delivery system for breast cancer therapy. The review categorizes LPHNPs and discusses their unique structure, preparation methods, and applications in cancer therapy. It delves into the various methods of preparing for LPHNPs. Furthermore, it examines the application of LPHNPs in treating various cancers, focusing on breast cancer, where they have shown promise in delivering single drugs, drug combinations, and nucleic acids like siRNA and miRNA. The ability of LPHNPs to overcome drug resistance and enhance therapeutic efficacy is emphasized, along with their potential for personalized medicine. The literature search was performed using PubMed, Scopus, and Web of Science databases to identify relevant studies published from 2009 to 2025. The review summarizes recent patents related to breast cancer treatment, showcasing advancements in drug delivery systems and therapeutic approaches. The conclusion underscores the transformative potential of LPHNPs in revolutionizing breast cancer treatment, provided that challenges in formulation, scalability, and long-term safety are addressed. Continued research and collaboration between researchers, clinicians, and regulatory bodies are essential to realize the benefits of LPHNPs in personalized cancer therapy. [Figure: see text].